Related Experiment Video
Updated: Feb 11, 2026
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
Published on: July 21, 2023
Role of the blood coagulation cascade in hepatic fibrosis
Asmita Pant1,2, Anna K Kopec1,2, James P Luyendyk1,2,3
1Department of Pathobiology and Diagnostic Investigation, Michigan State University , East Lansing, Michigan.
Insights
Liver disease, especially cirrhosis, disrupts blood clotting, rebalancing the coagulation cascade. Coagulation factors like Xa and thrombin drive liver fibrosis, suggesting anticoagulation may reduce liver pathology.
Area of Science:
- Hepatology
- Hematology
- Biochemistry
Background:
- Liver diseases, particularly cirrhosis, are linked to blood clotting abnormalities.
- Cirrhosis involves a complex rebalancing of the coagulation cascade, not just bleeding risk.
- Prothrombotic factors correlate with faster fibrosis progression in liver disease.
Purpose of the Study:
- To review evidence for coagulation's role in liver fibrosis pathogenesis.
- To explore potential mechanisms linking coagulation to liver fibrosis.
- To discuss how animal studies inform clinical anticoagulation strategies for liver fibrosis.
Main Methods:
- Review of existing scientific literature and experimental animal studies.
- Analysis of evidence implicating coagulation proteases in profibrogenic events.
- Correlation of prothrombotic risk factors with fibrosis progression.
Main Results:
- Coagulation factor Xa and thrombin are implicated in driving profibrogenic events in the liver.
- Experimental animal studies provide strong evidence for coagulation's role in hepatic fibrosis.
- Emerging clinical data suggests anticoagulation may reduce liver fibrosis.
Conclusions:
- Coagulation plays a pathologic role in the development of liver fibrosis.
- Mechanisms involve coagulation proteases driving profibrogenic events.
- Anticoagulation may offer therapeutic benefits beyond thrombosis prevention, including reducing liver fibrosis.
Abstract:
Liver is the primary source of numerous proteins that are critical for normal function of the blood coagulation cascade. Because of this, diseases of the liver, particularly when affiliated with severe complications like cirrhosis, are associated with abnormalities of blood clotting. Although conventional interpretation has inferred cirrhosis as a disorder of uniform bleeding risk, it is now increasingly appreciated as a disease wherein the coagulation cascade is precariously rebalanced. Moreover, prothrombotic risk factors are also associated with a more rapid progression of fibrosis in humans, suggesting that coagulation proteases participate in disease pathogenesis. Indeed, strong evidence drawn from experimental animal studies indicates that components of the coagulation cascade, particularly coagulation factor Xa and thrombin, drive profibrogenic events, leading to hepatic fibrosis. Here, we concisely review the evidence supporting a pathologic role for coagulation in the development of liver fibrosis and the potential mechanisms involved. Further, we highlight how studies in experimental animals may shed light on emerging clinical evidence, suggesting that beneficial effects of anticoagulation could extend beyond preventing thrombotic complications to include reducing pathologies like fibrosis.
Related Concept Videos
01:14Hepatic Drug Clearance: Role of Transporters
01:24Intracellular Signaling Cascades
01:06Coagulation
01:09Coagulation
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:25Rab Cascades